Metformin Compared to Glyburide in Gestational Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00965991
Recruitment Status : Completed
First Posted : August 26, 2009
Last Update Posted : June 25, 2010
Information provided by:
University of New Mexico

Brief Summary:
Our hypothesis is that metformin and glyburide will have equal efficacy in controlling blood glucose in gestational diabetics with no increase in adverse maternal, fetal or neonatal outcomes.

Condition or disease Intervention/treatment Phase
Gestational Diabetes Drug: metformin Drug: Glyburide Not Applicable

Detailed Description:
Pregnant women are screened with a one hour 50g glucose challenge. Women with values of 130 mg/dl or greater are then given a 100g glucose tolerance test. Two abnormal values are diagnostic of gestational diabetes. all women are initially counseled on diet and exercise. Women who fail to maintain a fasting of <105mg/dl and 2 hr postprandial < 120 mg/dl are offered participation in the study. Women were randomized to either metformin or glyburide via a computer generated randomization. Women who fail to meet glycemic goals after receiving the maximum dose of study medication were considered treatment failures and insulin therapy was initiated.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 149 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Trial of Metformin Compared to Glyburide in Gestational Diabetes
Study Start Date : July 2003
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Metformin Drug: metformin
patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
Other Name: Glucophage

Active Comparator: Glyburide Drug: Glyburide
Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
Other Name: sulfonylurea

Primary Outcome Measures :
  1. glucose control [ Time Frame: fasting and 2 hour postprandial blood glucose ]

Secondary Outcome Measures :
  1. birthweight [ Time Frame: postpartum ]
  2. delivery method [ Time Frame: postpartum ]
  3. failure rate of the drug to control blood glucose [ Time Frame: at weekly visit ]
  4. fetal macrosomia [ Time Frame: postpartum ]
  5. neonatal hypoglycemia [ Time Frame: postpartum ]
  6. maternal hypoglycemia [ Time Frame: postpartum ]
  7. birth trauma [ Time Frame: postpartum ]
  8. NICU admission [ Time Frame: postpartum ]
  9. APGARs [ Time Frame: postpartum ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Gestational diabetes not controlled with diet and exercise

Exclusion Criteria:

  • history of alcohol misuse
  • history of drug misuse
  • Chronic hypertension requiring medication
  • Renal failure
  • Hepatic disease or dysfunction
  • Known fetal anomaly
  • Inability to give consent
  • known allergy to metformin or glyburide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00965991

United States, New Mexico
University of New Mexico Diabetes in Pregnancy Clinic
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Principal Investigator: Lisa E Moore, MD University of New Mexico

Publications of Results:
Responsible Party: Lisa E. Moore,MD, University of New Mexico Identifier: NCT00965991     History of Changes
Other Study ID Numbers: HRRC#03-277
First Posted: August 26, 2009    Key Record Dates
Last Update Posted: June 25, 2010
Last Verified: May 2008

Keywords provided by University of New Mexico:
Gestational diabetes
oral agents

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Hypoglycemic Agents
Physiological Effects of Drugs